Introduction
Fibrous histiocytomas can be classified as benign and malignant. Benign fibrous histiocytomas (BFHs) can be further sub-divided by tissue of origin, either dermal or deep (subcutaneous). Cutaneous benign fibrous histiocytoma, or dermatofibroma, is localized to the dermis and characterized by an assortment of spindle and/or rounded cells.
1 It is a common lesion seen in many age groups, with predominance in the 3rd and 4th decades of life, and gender distribution varying by population. 1 The majority of lesions are found on and are more well circumscribed/encapsulated than the cutaneous form. 2 Metastasis has yet to be reported.
Malignant fibrous histiocytoma (MFH) was first described by O'Brien and Stout in 1964. 4 Malignant fibrous histiocytoma was historically thought to be the malignant and undifferentiated counterpart of the BFH. Recent advances have changed our understanding of their cell origin, resulting in reclassification as undifferentiated pleomorphic sarcoma. However, many clinicians continue to use the broader term MFH. In adults, MFH is the second most common soft tissue sarcoma (STS), with an incidence of 0.88 cases per 100,000 annually. 5 It occurs more commonly in men (2:1, Male:
Female), and the incidence increases with age. 5, 6 Malignant fibrous histiocytoma is one of the most commonly diagnosed sarcomas in patients with prior radiation exposure in the head or neck region. 7 The most common locations of these tumors in order are the head and neck, the extremities, the trunk, and the retroperitoneum. 8 Those occurring on the head and neck might exhibit a more aggressive course; one study reported a 5-year overall survival of 48% for patients with head and neck tumors compared with 77% for patients with trunk or extremity tumors.
9
The clinical presentation typically involves a painless, enlarging nodule that can become painful if enlarging rapidly. 8 Identification often involves histologic and immunohistochemical evaluations. Treatment typically involves wide local excision, en bloc resection with 2cm margins of uninvolved tissue, or Mohs surgery. 8, 10 However, local recurrence rates are high, ranging from 25 to 75%. 5, 8 Additional treatment with adjuvant radio-or chemotherapy should be considered on an individual case basis.
11
Malignant or benign fibrous histiocytoma involvement of the tongue is considerably rare, and offers additional symptomatology, such as difficulty speaking or swallowing.
12,13
Our review of the available literature identified 20 published cases. Thus, the present review serves to comprehensively describe previously published cases of BFH and MFH involving the tongue and aggregate information involving the rare presentation of this tumor entity.
Review of the Literature Literature Search
The National Library of Medicine PubMed database was searched for articles discussing dermatofibromas and dermatofibrosarcomas, or fibrous histiocytomas affecting the tongue. The following search terms were used: tongue and lingual combined with undifferentiated pleomorphic sarcoma, dermatofibroma, fibrous histiocytoma, and dermatofibrosarcoma. The articles were screened for relevance based on title and abstract. Potentially relevant articles were subsequently reviewed in full-text for final inclusion decision. Additionally, the references of each included article were screened for additional potentially relevant articles. Potentially relevant articles were case reports or case series or studies discussing fibrous histiocytomas affecting the tongue that described patient-level data and met the inclusion criteria. The inclusion criteria were: articles discussing the clinical course of cases of lingual fibrous histiocytoma, including presentation, diagnostic workup, treatment, and outcome. Articles were excluded if they did not contain patient-level data and/or original data (that is, literature reviews), did not pertain to the present topic, or were published in a language other than English. Of the included articles, patient-level data was extracted and discussed in the present review.
The search of the PubMed database through September 2016 (►Fig. 1) returned 234 articles. Screening by title and abstract left 18 potentially relevant articles for full-text review. Upon full-text review, two studies were excluded for having diagnoses that did not meet the inclusion criteria (that is, a diagnosis other than fibrous histiocytoma). Two additional articles were found to meet the inclusion criteria upon the screening of the article citations. Ultimately, a group of 18 articles, describing 20 
Clinical Presentation
The demographic profiles of fibrous histiocytomas, summarized in ►Table 1, were markedly different between the benign and malignant tumors. The mean patient age for BFH was 25.8 (range, 8-51) years, whereas MFH appears to affect an older population, with a mean age of 46.6 (range, 0.4-72) years. Additionally, the benign form reportedly had a marked predilection for females, with 80.0% of cases involving female patients versus 40.0% of cases involving female patients in the malignant form. The cases generally presented as a gradually progressive, painless nodule on the tongue with a firm and/or rubbery, elastic texture. The benign cases demonstrated no overt epithelial disruption. The malignant tumors were slightly larger than the benign ones, with an average diameter of 2.92 cm and 2.48 cm respectively. The malignant cases often presented as gray/white, ulcerated, or fungating lesions (n ¼ 8; 53.3%) that may have affected tongue movement (n ¼ 2; 13.3%). Single cases reported physiologic effects of the tumor, such as dysphagia, hoarseness, and sore throat. Cervical lymphadenopathy was not reported in any benign or malignant cases. However, constitutional symptoms such as weight loss and fever were reported in single cases. The duration of the symptoms was 3.6 (range, 0-12) months on average for the malignant cases. Benign cases presented later, at 5.0 (range, 2-7) months.
Workup
Blood chemistry values were rarely reported and otherwise generally unremarkable. Diagnostic imaging studies were reported in two malignant cases, and minimally discussed. The diagnosis was made with histopathologic evaluation in all cases. Tissue was usually procured through excisional or incisional biopsy, though one case employed the use of fine needle aspiration (FNA). Histopathological evaluation was the primary diagnostic modality; the most commonly observed histopathologic features are summarized in ►Table 2. On the histopathologic evaluation (►Fig. 2), BFH lesions were predominantly composed of plump spindle-shaped fibroblasts arranged in a storiform pattern. Scattered histiocytes were present and demonstrated pale and/or round nuclei, though occasional mitotic figures were present in two cases. The MFH cases exhibited pleomorphic cells that were haphazardly arranged with occasional storiform foci. Mitotic figures were present in the majority of cases (n ¼ 8 of 13, 61.5%). The spindle-shaped fibroblasts cells were reported to have ovoid, elongated nuclei with dense clumped chromatin. The histiocyte-like cells were hyperchromatic with lobulated nuclei and a granular or foamy cytoplasm. Multinucleated giant cells were present in 8 cases (61.5%), and exhibited pleomorphic nuclei.
The immunohistochemistry results (summarized in ►Table 2) were reported in 4/5 BFH and in 6/15 MFH cases, and were primarily valuable for diagnostic exclusion. The reported immunostains were as follows: α1-antitrypsin, α1-antichymotrypsin, CD117, CD31, CD34, CD68, carcinoembryonic antigen (CEA), cytokeratin, desmin, factor VIII, keratin, K i -67 protein, Leu7, S100, smooth muscle actin, and vimentin. One to two malignant and benign cases were reported to have α1-antitrypsin, α1-antichymothrypsin, CD34, CD68, smooth muscle actin, and vimentin immunoreactivity. Benign and malignant cases were both consistently negative for desmin and S100 staining.
Treatment and Outcome
The treatment and outcomes of the included cases are summarized in ►Table 3. All BFHs were treated surgically with local excision (n ¼ 4, 80.0%) or CO 2 laser excision (n ¼ 1, 20%). The single recurrent case, initially excised with CO 2 laser, was treated with subsequent hemiglossectomy. No cases of benign tumors received radiation or chemotherapy. At an average follow-up of 44.6 months, all benign cases were reported to be disease free.
Malignant tumors were primarily treated with surgery. Resection/excision was performed in 4 cases (n ¼ 4; 26.7%). Partial or hemiglossectomy was performed in 6 cases (n ¼ 6; 40.0%); Total glossectomy was performed in 1 case (n ¼ 1; 6.7%). Neck dissection was performed in 4 (26.7%) cases to evaluate the cervical lymph nodes for possible metastasis. Adjuvant radiotherapy was administered in 8 (53.3%) cases, often for recurrent disease or for suspicion of metastasis, with various modalities: iridium or radium implant/brachytherapy, telecobalt therapy, or unspecified external beam radiotherapy, and the results varied. Adjuvant chemotherapy was administered in 4 (26.7%) cases, also often for recurrence or metastasis. Combination chemotherapy regimens included doxorubicin þ dacarbazine, actinomycin D þ vincristine sulfate þ cyclophosphamide, or cyclophosphamide þ vincristine þ doxorubicin þ dacarbazine (CYVADIC). Recurrence occurred in 6 (40.0%) cases. At an average follow-up of 24.1 (range, 9-37) months, 8 (53.3%) cases were disease-free. In 7 (46.6%) cases, the patients succumbed to disease at an average of 19 (range, 9-34) months. All cases are summarized in ►Table 4. Notes: Percent may add up to more than 100 due to patients receiving multiple treatment modalities. Reported case numbers (n) may add up to more than the total number of cases (BFH ¼ 5; MFH ¼ 15) due to patients receiving multiple treatment modalities. This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. 32 The nomenclature of MFH subtypes was also changed to the following: storiform-pleomorphic MFH/undifferentiated high-grade pleomorphic sarcoma, giant cell MFH/ undifferentiated pleomorphic sarcoma with giant cells, and inflammatory MFH/undifferentiated pleomorphic sarcoma with prominent inflammation. These 3 subtypes remained within the "so-called fibrohistiocytic tumors" category, while myxoid MFH/myxofibrosarcoma, now a separate entity, has been moved to the myofibroblastic tumor category.
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Final Comments
The present review of the available literature returned 5 cases of BFH and 15 cases of MFH. The BFH cases demonstrated an apparent predilection for female (80.0% versus 40.0% in MFH) and younger (25.8 versus 46.6 in MFH) patients than MFH. The benign cases presented as a slowly growing, asymptomatic nodule with a firm, rubbery and elastic texture. The lesions were diagnosed by histopathologic evaluation with immunostaining used primarily for diagnostic exclusion. Of the BFH cases treated with first-line surgical excision, no recurrences were reported, whereas the case treated with initial CO 2 laser required subsequent hemiglossectomy for tumor recurrence. Malignant tumors presented as gray/white, ulcerated, fungating lesions with an average diameter of 2.92 cm. A minority of cases reported physiologic effects of the tumor, including affected tongue motility, dysphagia, hoarseness, and sore throat. The histopathologic workup demonstrated pleomorphic cells with occasional storiform patterns. Mitotic figures were present, with a mix of spindle-shaped fibroblast-like cells, histiocyte-like cells, and multinucleated giant cells. The surgical treatment is first-line, and adjuvant radiotherapy may be considered. Combination chemotherapy regimens vary. Recurrence occurred in 40.0% of cases (follow-up of 24.1 months), with death due to disease in 46.6% of patients (follow-up of 19.0 months).
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